Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: Toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers Journal Article
| Authors: | Jurczak, W.; Kroll-Balcerzak, R.; Giebel, S.; Machaczka, M.; Giza, A.; Ogórka, T.; Fornagiel, S.; Rybka, J.; Wróbel, T.; Kumiega, B.; Skotnicki, A. B.; Komarnicki, M. |
| Article Title: | Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: Toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers |
| Abstract: | Lymphomas with primary or secondary involvement of central nervous system (CNS) have poor prognosis despite specific treatment protocols which include whole brain radiotherapy and high-dose systemic and/or intrathecal chemotherapy. Toxicity of intrathecal liposomal cytarabine-based regimens collected between November 2006 and January 2012 was assessed retrospectively. Data from 120 adult lymphoma patients with, or at high risk of CNS involvement who received intrathecal liposomal cytarabine-based regimens at six Polish Lymphoma Research Group centres between November 2006 and January 2012 were assessed retrospectively. Patients were divided into three cohorts: A (high risk of CNS disease, n = 88), B (cerebrospinal fluid pleocytosis without neurological symptoms or pathological imaging findings, n = 7), and C (CNS disease/neurological involvement; n = 25). In all examined groups, toxicity of treatment was found to be acceptable (including the prophylactic setting). None of the patients in cohorts A or B who took intrathecal liposomal cytarabine 50 mg, repeated every 2–4 weeks (mean 3.8 doses) had experienced a CNS relapse at a median follow-up time of 3 years. Patients in cohort C had a 76 % overall neurological response rate (including a 40 % complete response rate) and median overall survival of 4.8 years. Regimens incorporating liposomal cytarabine seem to be safe and effective treatments for lymphomas with CNS involvement. © 2015, The Author(s). |
| Keywords: | adult; cancer chemotherapy; cancer survival; treatment response; unclassified drug; major clinical study; overall survival; cancer recurrence; drug efficacy; drug safety; primary central nervous system lymphoma; cytarabine; methotrexate; follow up; cancer prevention; nausea; dizziness; fever; cerebrospinal fluid; prophylaxis; headache; toxicity; spinal cord disease; pleocytosis; cns lymphoma; human; male; female; priority journal; article; intrathecal liposomal cytarabine; liposomal cytarabine |
| Journal Title: | Medical Oncology |
| Volume: | 32 |
| Issue: | 4 |
| ISSN: | 1357-0560 |
| Publisher: | Humana Press Inc |
| Date Published: | 2015-02-01 |
| Start Page: | 90 |
| Language: | English |
| DOI: | 10.1007/s12032-015-0520-3 |
| PROVIDER: | scopus |
| PMCID: | PMC4341025 |
| PUBMED: | 25716885 |
| DOI/URL: | |
| Notes: | Export Date: 2 April 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work